<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437382</url>
  </required_header>
  <id_info>
    <org_study_id>P17.161</org_study_id>
    <secondary_id>ZonMW</secondary_id>
    <nct_id>NCT03437382</nct_id>
  </id_info>
  <brief_title>Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study</brief_title>
  <acronym>HORA EST HCC</acronym>
  <official_title>HOlmium Radioembolization as Adjuvant Treatment to Radiofrequency Ablation for Early STage Hepatocellular Carcinoma (HORA EST HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Holland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quirem Medical B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maag Darm Lever stichting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center, dose-finding study, patients with early stage hepatocellular carcinoma
      according to the Barcelona Clinic Liver Cancer (BCLC) staging system will be included to
      receive percutaneous radiofrequency ablation in combination with RFA with adjuvant segmental
      radioembolization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RFA + adjuvant radioembolsation with Quirem Spheres
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single-arm, interventional, dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-finding</measure>
    <time_frame>1 year</time_frame>
    <description>Treatment area dose that will result in delivery of a radiation absorbed dose of ≥ 120Gy to the target area in at least 90% of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicity of RFA with adjuvant segmental radioembolization as assessed by complications according to CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tumor recurrence</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Local tumor recurrence at 6 months as assessed by multiphase CT or dynamic MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year</time_frame>
    <description>time until disease progresses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Kaplan-Meier analysis of progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Throughout the first year after treatment.</time_frame>
    <description>Quality of Life will be assessed by means of the EORTC QLQ HCC-18 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Throughout the first year after treatment.</time_frame>
    <description>Quality of Life will be assessed by means of the C-30 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HCC</condition>
  <condition>Early Stage HCC</condition>
  <arm_group>
    <arm_group_label>RFA + radioembolization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Quirem Medical Holmium-166 radioembolization microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quirem Medical Holmium-166 radioembolization microspheres</intervention_name>
    <description>radioembolisation as adjuvant treatment to RFA</description>
    <arm_group_label>RFA + radioembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age &gt; 18 years

          -  Single HCC lesion with diameter of ≥ 2-5cm or up to three lesions with each lesion
             measuring no more than 3cm (confined to one lobe)

          -  HCC diagnosis is based on histology or non-invasive imaging criteria according to
             EORTC-EASL guidelines

          -  Child Pugh A or B ≤7

          -  ECOG performance status ≤ 2

          -  Bilirubin &lt; 2mg/dL

          -  ASAT &lt; 5x upper limit of normal

          -  ALAT &lt; 5x upper limit of normal

          -  Thrombocytes ≥ 50 X 10^9/L

        Exclusion Criteria:

          -  Recurrent HCC

          -  Tumor location precluding percutaneous RFA

          -  Bilobar tumor involvement

          -  Vascular tumor invasion or extrahepatic metastasis

          -  Hemihepatectomy

          -  Severe comorbidity (e.g. cardiovascular disease, diabetes with nephropathy, active
             infections)

          -  Uncorrectable coagulopathy

          -  Large arterio-portovenous shunt

          -  Previous radiotherapy to the liver

          -  Surgical hepatico-enterostomy

          -  Hepatic resection with placement of surgical clips that may cause artefacts on MRI

          -  Incompetent/ mentally disabled

          -  Pregnancy, inadequate anticonception

          -  Calculated lung dose &gt;30Gy

          -  Creatinine clearance &lt; 50 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Burgmans, MD, PhD</last_name>
    <phone>+31-71 5262410</phone>
    <email>m.c.burgmans@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pim Hendriks, MSc.</last_name>
    <phone>+31-71 5298161</phone>
    <email>p.hendriks@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Burgmans, MD, PhD</last_name>
      <phone>+31-71 5262410</phone>
      <email>m.c.burgmans@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pim Hendriks, MSc.</last_name>
      <phone>+31-71 5298161</phone>
      <email>p.hendriks@lumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>MCBurgmans</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Radiofrequency ablation (RFA)</keyword>
  <keyword>Radioembolization</keyword>
  <keyword>Quirem Spheres</keyword>
  <keyword>Selective internal radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

